Recombinant MS4A1 (Rituximab Biosimilar) anticorps

N° du produit ABIN7200660

Détail du produit anti-MS4A1 (Rituximab Biosimilar) anticorps

Antigène: MS4A1 (Rituximab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp MS4A1 (Rituximab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Fonction: Rituximab Biosimilar, CD20 Monoclonal Antibody

Specificité: The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.

Attributs du produit: Recombinant Humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.

Clone: 10F381

Isotype: IgG1 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur MS4A1 (Rituximab Biosimilar)

Antigène: MS4A1 (Rituximab Biosimilar)

Abstract: MS4A1 (Rituximab Biosimilar) Produits

Synonymes: anticorps B1, anticorps Bp35, anticorps CD20, anticorps CVID5, anticorps LEU-16, anticorps MS4A2, anticorps S7, anticorps membrane spanning 4-domains A1, anticorps MS4A1

Classe de substances: Biosimilar

Sujet: B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.

Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.